Video

Dr. Lee discusses the benefits of robotic surgery in prostate cancer

Author(s):

Urology Times staff

“Your vision is better, your instruments are better, and so we can do an excellent cancer operation while maintaining really good rates of continence and potency recovery,” says David Lee, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      David Lee, MD, professor of Clinical Urology at UCI Health, discusses the benefits of robotic surgery in patients with prostate cancer. Lee is a robotic surgery expert who has completed more than 6300 robotic surgical procedures.

      Related Videos
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Related Content
      Combination therapy linked to longer OS vs ADT in veterans with mHSPC
      May 27th 2025

      Combination therapy linked to longer OS vs ADT in veterans with mHSPC

      Hannah Clarke
      However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
      May 20th 2025

      Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

      Hannah Clarke
      Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Study shows value of precision-based approaches in prostate cancer
      May 19th 2025

      Study shows value of precision-based approaches in prostate cancer

      Hannah Clarke
      The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
      SBRT may offer a safe alternative to CFRT after prostatectomy
      May 16th 2025

      SBRT may offer a safe alternative to CFRT after prostatectomy

      Hannah Clarke
      Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
      © 2025 MJH Life Sciences

      All rights reserved.